Select Page

MVA Members


Contract Manufacturing Organisation

Fareva is a family owned french CDMO, the largest one in France and employs more than13,000 people globally, distributed in 41 production sites located in 13 countries in EMEA and the Americas.

18 of the Fareva sites (including the latest acquisitions) are dedicated to pharmaceutical activities. We have industry leading capabilities in development & manufacturing of a large range of Drug Products and Active Pharmaceutical Ingredients (APIs).

Fareva capabilities support a broad range of therapeutic areas including vaccines, oncology, antibiotics, biologics, OTC, animal health and ophthalmic products.

Fareva’s API division has operations in 3 European sites located in France and Germany and these sites are EMA and US-FDA inspected, specialising in development & optimisation of complex, multi-step synthesis of APIs & Advanced Intermediates. The group has niche technologies for high potent APIs (HPAPIs) down to the OEB-6 level, aseptic crystallization (sterile APIs), Spray Drying etc, with volumes ranging from a few kgs to multi tons production. FAREVA is also the first and only company in the world to receive SafeBridge Certification to handle both high potent drug substance and drug product at the same facility. Link to more info on the website-

Fareva’s Drug Product division offers different technologies: injectables (lyophilized, solution, suspension, vial, ampoules, pre-filled syringes), unidoses and multidoses BFS, solids (tablets, hard capsules, powders), semi-solids (cream, gel suppositories) and liquids (oral and external, sprays, aerosols). And can fill into wide range of presentations (vials, pre-filled syringe, cartridges, unidose and multidose BFS, bottles, tubes, sachet, suppositories, blisters etc.) assist in tech transfer activities to facilitate smooth integration into our facility.

Link to more info on the website –

We are able to support our customers from early clinical phase programs, requiring small scale manufacturing, process optimisation and scale-up, to launch and commercial phases.

All sites are state of the art cGMP and accredited by several international pharmaceutical agencies such as FDA, ANVISA, Russia, Japan, China and others.